SCHEMBL3970321

SCHEMBL3970321

[CH2]c1cc([N+](=O)[O-])cc2[nH]c(C)nc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.40
TSHR P16473 1/20 0.40
NPBWR1 P48145 5/20 0.40
ALDH1A1 P00352 3/20 0.40
RAB9A P51151 3/20 0.40
MAPT P10636 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
NPC1 O15118 2/20 0.40
MEN1 O00255 1/20 0.40
NFKB1 P19838 1/20 0.40
MAPK1 P28482 1/20 0.40
NFKB2 Q00653 1/20 0.40
KMT2A Q03164 1/20 0.40
RELA Q04206 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
KDM4E B2RXH2 1/20 0.38
LMNA P02545 1/20 0.37
CYP3A4 P08684 1/20 0.37
ALOX15 P16050 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15022789 0.81 NQO2 (0.48) HTTTSHRNPBWR1ALDH1A1RAB9A
SCHEMBL7029112 0.81 HTT (0.48) HTTTSHRNPBWR1ALDH1A1RAB9A
SCHEMBL3969162 0.80 NPBWR1 (0.37) HTTTSHRNPBWR1ALDH1A1RAB9A
SCHEMBL7261468 0.78 ALDH1A1 (0.41) HTTTSHRNPBWR1ALDH1A1RAB9A
SCHEMBL3964658 0.78 HTT (0.40) HTTTSHRNPBWR1ALDH1A1RAB9A
SCHEMBL2919366 0.77 DHODH (0.57) MAPTMAPK1
SCHEMBL2921100 0.77 PKM (0.39) HTTTSHRNPBWR1ALDH1A1RAB9A
SCHEMBL12999439 0.74 KMT2A (0.42) HTTALDH1A1RAB9AMAPTSMN1; SMN2
SCHEMBL3973306 0.73 HTT (0.68) HTTALDH1A1CSNK2A1
SCHEMBL4328218 0.70 ALDH1A1 (0.69) HTTNPBWR1ALDH1A1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7595317-B2 Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-29 US disclosed
US-7294624-B2 Osteoporosis; antiarthritic agents BRISTOL MYERS SQUIBB COMPANY (US) 2007-11-13 US disclosed
US-20070167451-A1 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES DUAN JINGWU 2007-07-19 US disclosed
WO-2003040103-A1 β-SULFONE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE) BRISTOL-MYERS SQUIBB COMPANY (US) 2003-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167451-A1 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES TNF, MMP9, MMP3 HTT 4656/4885TSHR 1067/4885NPBWR1 350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.